---
title: Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With
  AML Treated With Venetoclax and Azacitidine
date: '2024-08-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39133921/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240813182051&v=2.18.0.post9+e462414
source: Blood
description: European LeukemiaNet (ELN) acute myeloid leukemia (AML) genetic risk
  classification systems were based on response to intensive chemotherapy; their ability
  to discriminate outcomes in older patients treated with venetoclax-azacitidine may
  be suboptimal. Here, pooled analysis of patients in the phase 3 VIALE-A trial (NCT02993523)
  and phase 1b study (NCT02203773) examined prognostic stratification according to
  2017 and 2022 ELN risk classifications. A bioinformatic algorithm derived new ...
disable_comments: true
---
European LeukemiaNet (ELN) acute myeloid leukemia (AML) genetic risk classification systems were based on response to intensive chemotherapy; their ability to discriminate outcomes in older patients treated with venetoclax-azacitidine may be suboptimal. Here, pooled analysis of patients in the phase 3 VIALE-A trial (NCT02993523) and phase 1b study (NCT02203773) examined prognostic stratification according to 2017 and 2022 ELN risk classifications. A bioinformatic algorithm derived new ...